|
The ASCO Cancer Foundation has awarded 100 oncology fellows with a 2008 Merit Award, honoring their work as the first authors of outstanding Meeting abstracts. Abstracts eligible for Merit Award consideration are evaluated during the normal abstract review period by the Scientific Program Committee, with the Pediatric Subcommittee selecting the top abstract in its category for the Brigid Leventhal Award. The monetary awards are provided by The ASCO Cancer Foundation and are intended to aid young physicians with travel expenses for the Annual Meeting. More importantly, the award recognition supports further research in clinical oncology.
A complete list of all Merit Award recipients who will present research today follows and includes the time and location of each session. Each edition of ASCO Daily News will include such a list.
2008 Merit Award Winners Presenting Today
Giovanni D. Aletti, MD
The Mayo Foundation
“Debulk or not debulk? An answer to an Hamletic dilemma using a multi-institutional risk-adjusted model for evaluation of outcomes” (Abstract 5541)
General Poster Session, Gynecologic Cancer
8:00 AM–12:00 PM • Hall A1, South Building
Joshua Brody, MD
Stanford University Medical Center
(Bradley Stuart Beller Merit Award Recipient)
“Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909” (Abstract 3003)
Oral Presentation, Developmental Therapeutics: Immunotherapy
3:00 PM–6:00 PM • Room W375A, West Building
Kathryn R. Chan, MD
Thomas Jefferson University
“A pilot study using sunitinib malate as therapy in patients with stage IV uveal melanoma” (Abstract 9047)
General Poster Session, Melanoma
2:00 PM–6:00 PM • Hall A1, South Building
Timothy R. Donahue, MD
University of California, Los Angeles
“Impact of neoadjuvant therapy on histopathologic response and survival in patients with primary high-grade retroperitoneal soft tissue sarcomas” (Abstract 10510)
Oral Presentation, Sarcoma
3:00 PM–6:00 PM • Room W375B, West Building
Todd A. Fehniger, MD, PhD
Washington University
“Preliminary results of a phase II study of high dose lenalidomide as initial therapy for acute myeloid leukemia in patients 60 years old” (Abstract 7058)
General Poster Session, Leukemia, Myelodysplasia, and Transplantation
8:00 AM–12:00 PM • Hall A1, South Building
Kathryn M. Field, MBBS
Peter MacCallum Cancer Centre
“Complementary and alternative medicine (CAM) use in high-risk women in the Kathleen Cunningham Foundation Consortium for Research into Familial Breast cancer (kConFab)” (Abstract 1528)
General Poster Session, Cancer Prevention
2:00 PM–6:00 PM • Hall A1, South Building
Hilary Glen, MB, ChB, MSc
Beatson Institute for Cancer Research
“A phase I study of E7080 in patients (pts) with advanced malignancies” (Abstract 3526)
Poster Discussion, Developmental Therapeutics: Molecular Therapeutics
8:00 AM–12:00 PM • W375E Lobby, West Building
Nitin Jain, MD
M. D. Anderson Cancer Center
“Synthetic tumor-specific breakpoint peptide vaccine in patients (pts) with chronic myeloid leukemia (CML) and minimal residual disease: A phase II trial” (Abstract 7056)
General Poster Session, Leukemia, Myelodysplasia, and Transplantation
8:00 AM–12:00 PM • Hall A1, South Building
Yelena Y. Janjigian, MD
Memorial Sloan-Kettering Cancer Center
“Pack years of cigarette smoking as a predictor of survival in 2,013 patients with stage IIIb/IV non-small cell lung cancer (NSCLC)” (Abstract 8005)
Clinical Science Symposium, Non-Smoking-Related Lung Cancers
1:15 PM–2:45 PM • Room W375D, West Building
Rajini Katipamula, MBBS
Mayo Clinic
“Trends in mastectomy rates at the Mayo Clinic Rochester: Effect of surgical year and pre-operative MRI” (Abstract 509)
Oral Presentation, Breast Cancer — Local-regional and Adjuvant Therapy
2:45 PM–6:00 PM • Hall B1, North Building
Chris C. Lee, MD
John Wayne Cancer Institute
“Improved survival for stage IV melanoma from an unknown primary site” (Abstract 9031)
General Poster Session, Melanoma
2:00 PM–6:00 PM • Hall A1, South Building
Richard T. Lee, MD
University of Chicago
“Older cancer survivors’ use of biologically based complementary and alternative medicine (CAM): A national, population-based study in the United States” (Abstract 9508)
Clinical Science Symposium, Innovative Research in Aging and Cancer
4:30 PM–6:00 PM • Room S100A, South Building
Hongmei Liang, MD, PhD
University of Pittsburgh Cancer Institute
“Correlation of serum sex hormone levels with the Gail model risk of breast cancer in post-menopausal women” (Abstract 1517)
General Poster Session, Cancer Prevention
2:00 PM–6:00 PM • Hall A1, South Building
Ravi A. Madan, MD
National Cancer Institute
“Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): Implications for clinical trial design” (Abstract 3005)
Oral Presentation, Developmental Therapeutics: Immunotherapy
3:00 PM–6:00 PM • Room W375A, West Building
David Olmos, MD, PhD
Royal Marsden Hospital
“Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in sarcoma patients” (Abstract 10501)
Clinical Science Symposium, Emerging Targets for Sarcoma Therapy
8:00 AM–9:30 AM • Room W375D, West Building
Cecile Ortholan, MD
Centre Antoine Lacassagne
“Head and neck squamous cell carcinoma in patients over 80 years old: patterns of care and survival” (Abstract 6050)
General Poster Session, Head and Neck Cancer
2:00 PM–6:00 PM • Hall A1, South Building
Emanuela Palmerini, MD
Instituto Ortopedico Rizzoli
“Synovial sarcoma: A retrospective analyis of 250 patients treated in a single institution” (Abstract 10506)
Oral Presentation, Sarcoma
3:00 PM–6:00 PM • Room W375B, West Building
Min S. Park, MD
M. D. Anderson Cancer Center
“Combination therapy with temozolomide and bevacizumab in the treatment of hemangioperi-cytoma/malignant solitary fibrous tumor” (Abstract 10512)
Oral Presentation, Sarcoma
3:00 PM–6:00 PM • Room W375B, West Building
Premal H. Patel, MD, PhD
Memorial Sloan-Kettering Cancer Center
“Hypoxia-inducible factor (HIF) 1alpha and 2alpha; levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC)” (Abstract 5008)
Clinical Science Symposium, VEGF Pathway,
Renal Cancer, and Its Treatment
1:15 PM–2:45 PM • Room W375E, West Builidng
Lee P. Resta, MD
Sidney Kimmel Comprehensive Cancer Center
“Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer” (Abstract 3529)
Poster Discussion, Developmental Therapeutics: Molecular Therapeutics
8:00 AM–12:00 PM • W375E Lobby, West Building
David Schreiber, MD
State University of New York DownstateMedical Center
“Surgery for limited-stage small cell lung cancer, should the paradigm shift? A SEER-based analysis” (Abstract 7525)
Poster Discussion, Lung Cancer — Local-regional and Adjuvant Therapy
2:00 PM–6:00 PM • W375E Lobby, West Building
Marcin Skrzypski, MD
ICO Hospital Germans Trias i Pujol
“Validation of 5- and 3-gene expression signatures for predicting outcome in non-small cell lung cancer (NSCLC) patients (p)” (Abstract 7532)
Poster Discussion, Lung Cancer — Local-regional and Adjuvant Therapy
2:00 PM–6:00 PM • W375E Lobby, West Building
Hanne Stensheim, MD
Cancer Registry of Norway
“Reproduction after cancer: A nationwide, population-based study” (Abstract 9646)
General Poster Session, Patient and Survivor Care
2:00 PM–6:00 PM • Hall A1, South Building
Shannon Westin, MD
M. D. Anderson Cancer Center
“Survivors of gynecologic malignancies (GYN CA): Impact of treatment on health and well-being” (Abstract 5527)
Poster Discussion, Gynecologic Cancer
2:00 PM–6:00 PM • Room S403AB, South Building
Lauren Wiebe, MD
University of Chicago
“Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium” (Abstract 10502)
Clinical Science Symposium, Emerging Targets for Sarcoma Therapy
8:00 AM–9:30 AM • Room W375D, West Building
|
